Context Cash Flow Coverage Ratios from 2010 to 2024

CNTX Stock  USD 1.29  0.10  7.19%   
Context Therapeutics Cash Flow Coverage Ratios yearly trend continues to be fairly stable with very little volatility. Cash Flow Coverage Ratios is likely to outpace its year average in 2024. During the period from 2010 to 2024, Context Therapeutics Cash Flow Coverage Ratios regression line of annual values had significance of  0.0007 and arithmetic mean of (69.68). View All Fundamentals
 
Cash Flow Coverage Ratios  
First Reported
2010-12-31
Previous Quarter
(282.90)
Current Value
(268.76)
Quarterly Volatility
119.66532158
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Context Therapeutics Correlation against competitors.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' Cash Flow Coverage Ratios Growth Pattern

Below is the plot of the Cash Flow Coverage Ratios of Context Therapeutics over the last few years. It is Context Therapeutics' Cash Flow Coverage Ratios historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Flow Coverage Ratios10 Years Trend
Slightly volatile
   Cash Flow Coverage Ratios   
       Timeline  

Context Cash Flow Coverage Ratios Regression Statistics

Arithmetic Mean(69.68)
Coefficient Of Variation(171.75)
Mean Deviation101.99
Median(0.13)
Standard Deviation119.67
Sample Variance14,320
Range283
R-Value(0.77)
Mean Square Error6,211
R-Squared0.60
Significance0.0007
Slope(20.68)
Total Sum of Squares200,477

Context Cash Flow Coverage Ratios History

2024 -268.76
2023 -282.9
2021 -246.0
2020 -0.17

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Cash Flow Coverage Ratios, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Flow Coverage Ratios(282.90)(268.76)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.